Related Experiment Video
Updated: Dec 17, 2025

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Camptothecin induced DDX5 degradation increased the camptothecin resistance of osteosarcoma
Xingkai Zhao1, Miao Bao2, Fengmin Zhang3
1Department of Orthopedic Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China.
Abstract:
Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents. Unfortunately, chemo-resistance is a huge obstacle in the treatment of OS. However, the underlying molecular mechanisms of OS chemo-resistance still remain unknown. Here we reported that the resistance to camptothecin (cpt) therapy was driven by degradation of DDX5. DDX5 knockdown decreased cell death and DNA damage and recovered cell proliferation in cpt treated 143B cells. Furthermore, we found that DDX5 bound to NONO, a kind of DNA repairing protein, and regulated NONO functions. Our data verified that cpt-induced degradation of DDX5 following by breaking down the protein bound of NONO, which participated in the resistance of cpt. In the summary, according to our results, DDX5 might be a potential therapeutic target for improving clinical outcomes of cpt in OS.
Insights
Osteosarcoma chemo-resistance is linked to DDX5 protein loss. Restoring DDX5 may improve camptothecin treatment effectiveness in bone cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Osteosarcoma (OS) is a prevalent bone cancer in children and adolescents.
- Chemo-resistance significantly hinders effective OS treatment.
- The molecular basis of chemo-resistance in OS is not fully understood.
Purpose of the Study:
- To investigate the molecular mechanisms underlying chemo-resistance in osteosarcoma.
- To identify potential therapeutic targets for overcoming camptothecin resistance in OS.
Main Methods:
- Utilized 143B osteosarcoma cells.
- Investigated the role of DDX5 protein in camptothecin (cpt) resistance.
- Examined the interaction between DDX5 and NONO, a DNA repair protein.
Main Results:
- Camptothecin (cpt) resistance in OS cells was associated with the degradation of DDX5.
- Knockdown of DDX5 reduced cpt-induced cell death and DNA damage, enhancing cell proliferation.
- DDX5 regulates the function of the DNA repair protein NONO, and its degradation disrupts this interaction, contributing to cpt resistance.
Conclusions:
- DDX5 degradation is a key mechanism driving chemo-resistance to camptothecin in osteosarcoma.
- DDX5 may serve as a potential therapeutic target to enhance camptothecin efficacy in OS treatment.
Related Concept Videos
Treatment Resistant Cancers
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

